Bicara Therapeutics logo
Bicara Therapeutics
BCAX | NASDAQ
Chart Builder DCF Calculator
$9.75
-$0.27 (-2.69%)
At close: Nov 16, 2026, 4:00 PM ET
$9.75
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Bicara Therapeutics Company Profile

Company profile explained

Company Profile

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Key Executives

Name Position
Claire Mazumdar Clemon Chief Executive Officer & Director
Lara S. Meisner Chief Legal Officer, Compliance Officer & Corporate Secretary
Pauline Dufresne Chief People Officer
Ryan Cohlhepp President, Chief Operating Officer & Director
Angela Windt Vice President & Head of Regulatory Affairs
Jean-Paul Rodrique Senior Vice President & Global Head of Quality Assurance
Jeltje Schulten Senior Vice President of Clinical & Medical Affairs
Jenna Cohen Chief Corporate Affairs Officer
Jennifer Larson CFO, Treasurer & Principal Accounting Officer
Rachel Frank Vice President of Investor Relations and Corporate Communications
Rachel Salazar SVP of R&D Strategy and Operations
Sathish Hasige Senior Vice President and Head of Technical Operations & Supply Chain

Latest SEC Filings

Date Type Title
Oct 07, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 10, 2026 4 Filing
Sep 08, 2026 144 Filing
Sep 08, 2026 144 Filing
Aug 25, 2026 8-K Current Report
Aug 14, 2026 4 Filing
Aug 14, 2026 3 Filing
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 4 Filing
Aug 12, 2026 4 Filing
View All SEC Filings ➞
Bicara Therapeutics
Bicara Therapeutics logo
Country United States
IPO Date Sep 13, 2024
Industry Biotechnology
Sector Healthcare
Employees 103
CEO Claire Mazumdar Clemon

Contact Details

116 Huntington Avenue Boston, Massachusetts 02116 United States

Stock Details

Ticker Symbol BCAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0002023658
CUSIP Number 055477103
ISIN Number US0554771032
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.